Page last updated: 2024-10-28

haloperidol and As If Personality

haloperidol has been researched along with As If Personality in 21 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Research Excerpts

ExcerptRelevanceReference
"The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed."7.67[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988)
"The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed."3.67[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988)
"Haloperidol was superior to both amitriptyline and placebo on a composite measure of overall symptom severity, with no difference between amitriptyline and placebo."2.66Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. ( George, A; Nathan, RS; Perel, JM; Schulz, PM; Soloff, PH; Ulrich, RF, 1986)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-199016 (76.19)18.7374
1990's4 (19.05)18.2507
2000's1 (4.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Machida, N1
Shiotsuka, S1
Semba, J1
Conn, LM1
Lion, JR1
Serban, G1
Siegel, S1
Garbutt, JC2
Loosen, PT2
Berman, AL1
Jordan, J1
Heinz, P1
Rao, KA1
Adlakha, A1
Meloy, T1
Soloff, PH3
George, A3
Nathan, S1
Schulz, PM3
Cornelius, JR1
Herring, J1
Perel, JM3
Gunderson, JG1
Kadysheva, NM1
Mokhovikov, AN1
Mosketi, KV1
Kryzhanovskiĭ, GN1
Glenn, M1
Nathan, RS2
Ulrich, RF1
Rockland, LH1
Valenstein, M1
Maltbie, A1
Kaplan, P1
Leonard, DP1
Kidson, MA1
Shannon, PJ1
Brown, J1
James, N1
Voelkel, A1
Wong, GH1
Cock, RJ1
Radzuweit, H1
Knorr, W1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675]Phase 280 participants (Actual)Interventional2018-11-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Anxiety Rating Scale (HAM-A)

A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported

Interventionchange in score on a scale (Mean)
Placebo-2.41
Rexulti-4.88

Hamilton Depression Rating Scale (HAM-D)

A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported

Interventionchange in score on a scale (Mean)
Placebo-2.09
Rexulti-3.81

Barratt Impulsiveness Scale (BIS)

A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)

,
Interventionscore on a scale (Mean)
Visit 1Visit 8
Placebo76.5368.13
Rexulti72.2770.5

Borderline Evaluation of Severity Over Time (BEST)

A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported

,
Interventionscore on a scale (Mean)
Visit 1Visit 8
Placebo40.9029.15
Rexulti40.5423.15

Columbia Suicide Severity Rating Scale (CSSRS)

"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)

,
Interventionscore on a scale (Mean)
Visit 1Visit 8
Placebo1.150.23
Rexulti0.730.08

MINI International Neuropsychiatric Interview

A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)

,
InterventionParticipants (Count of Participants)
Major Depressive Episode (Current)Major Depressive Episode (Past)Manic Episode (Current)Manic Episode (Past)Hypomanic Episode (Current)Bipolar I Disorder (Current)Bipolar I Disorder (Past)Bipolar II Disorder (Current)Bipolar II Disorder (Past)Panic Disorder (Current)Panic Disorder (Lifetime)Agoraphobia (Current)Social Anxiety Disorder (Current)Obsessive Compulsive Disorder (Current)Post Traumatic Stress Disorder (Current)Alcohol Use Disorder (Past 12 months)Substance Use Disorder (Past 12 months)Any Psychotic Disorder (Current)Any Psychotic Disorder (Lifetime)Major Depressive Disorder with Psychotic Features (Current)Major Depressive Disorder with Psychotic Features (Past)Anorexia Nervosa (current)Bulimia Nervosa (Current)Binge Eating Disorder (Current)Generalized Anxiety Disorder (Current)Antisocial Personality Disorder (Lifetime)ADHD Combined Type (Current)ADHD Inattentive Type (Current)ADHD Hyperactive Type (Current)Tourette's Syndrome (Lifetime)Persistent Motor Tic Disorder (Lifetime)Provisional Vocal Tic Disorder (Lifetime)Provisional Tic Disorder (Lifetime)Specific PhobiaBody Dysmorphic Disorder (Current)
Placebo16122110000611763913110000042108201010043
Rexulti1818230000161099312880100144154411110012

Quality of Life Inventory (QOLI)

A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)

,
Interventionscore on a scale (Mean)
Visit 1Visit 8
Placebo28.8930.75
Rexulti28.7035.71

Self Report Version of Zanarini Scale

A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

,
Interventionscore on a scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5Visit 6Visit 7Visit 8
Placebo18.212.810.710.79.79.68.79.3
Rexulti17.610.97.98.07.06.66.05.8

Sheehan Disability Scale (SDS)

Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

,
Interventionscore on a scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5Visit 6Visit 7Visit 8
Placebo17.313.311.512.411.711.212.012.7
Rexulti15.810.77.87.87.07.96.97.7

Symptom Checklist-90 Revised

An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)

,
Interventionscore on a scale (Mean)
Visit 1Visit 8
Placebo26.1720.25
Rexulti25.4214.21

Zanarini Rating Scale for Borderline Personality Disorder

A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

,
Interventionscore on a scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5Visit 6Visit 7Visit 8
Placebo14.97.64.764.25.758.4
Rexulti14.96.75.34.44.54.943.1

Reviews

1 review available for haloperidol and As If Personality

ArticleYear
Pharmacologic approaches to violence.
    The Psychiatric clinics of North America, 1984, Volume: 7, Issue:4

    Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Be

1984

Trials

9 trials available for haloperidol and As If Personality

ArticleYear
Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol.
    The American journal of psychiatry, 1984, Volume: 141, Issue:11

    Topics: Adult; Borderline Personality Disorder; Clinical Trials as Topic; Double-Blind Method; Female; Follo

1984
A dramatic behavioral response to thyrotropin-releasing hormone following low-dose neuroleptics.
    Psychoneuroendocrinology, 1984, Volume: 9, Issue:3

    Topics: Adult; Borderline Personality Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind

1984
Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.
    Journal of clinical psychopharmacology, 1989, Volume: 9, Issue:4

    Topics: Amitriptyline; Borderline Personality Disorder; Depressive Disorder; Follow-Up Studies; Haloperidol;

1989
Pharmacotherapy for patients with borderline personality disorder.
    Archives of general psychiatry, 1986, Volume: 43, Issue:7

    Topics: Amitriptyline; Antipsychotic Agents; Borderline Personality Disorder; Clinical Trials as Topic; Doub

1986
Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.
    Archives of general psychiatry, 1986, Volume: 43, Issue:7

    Topics: Adolescent; Adult; Amitriptyline; Borderline Personality Disorder; Clinical Trials as Topic; Double-

1986
Paradoxical effects of amitriptyline on borderline patients.
    The American journal of psychiatry, 1986, Volume: 143, Issue:12

    Topics: Aggression; Amitriptyline; Borderline Personality Disorder; Clinical Trials as Topic; Double-Blind M

1986
Effect of tranquilizers on borderline and schizotypal patients questioned.
    The American journal of psychiatry, 1985, Volume: 142, Issue:5

    Topics: Borderline Personality Disorder; Clinical Trials as Topic; Haloperidol; Humans; Personality Disorder

1985
Letter: Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea.
    Lancet (London, England), 1974, Nov-16, Volume: 2, Issue:7890

    Topics: Behavior; Carbonates; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Haloperid

1974
Long-term effects of haloperidol on severely emotionally disturbed children.
    The Australian and New Zealand journal of psychiatry, 1971, Volume: 5, Issue:4

    Topics: Affective Symptoms; Child; Child Behavior Disorders; Clinical Trials as Topic; Female; Haloperidol;

1971

Other Studies

11 other studies available for haloperidol and As If Personality

ArticleYear
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2005, Volume: 107, Issue:7

    Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human

2005
The transition from inpatient to outpatient care.
    Suicide & life-threatening behavior, 1994,Fall, Volume: 24, Issue:3

    Topics: Adult; Combined Modality Therapy; Conversion Disorder; Disability Evaluation; Haloperidol; Humans; I

1994
Use of a revised version of the psychotropic medication efficacy graph.
    Mental retardation, 1994, Volume: 32, Issue:2

    Topics: Adult; Alprazolam; Haloperidol; Humans; Intellectual Disability; Male; Neurocognitive Disorders; Per

1994
[Accidental intravenous administration of haloperidol decanoate].
    Psychiatrische Praxis, 1996, Volume: 23, Issue:1

    Topics: Adult; Antipsychotic Agents; Crisis Intervention; Female; Haloperidol; Humans; Injections, Intraveno

1996
Tremor, confusion, and autonomic dysfunction in Down syndrome.
    Hospital practice (Office ed.), 1992, Aug-15, Volume: 27, Issue:8

    Topics: Adult; Autonomic Nervous System Diseases; Confusion; Diagnosis, Differential; Down Syndrome; Haloper

1992
[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1988, Volume: 88, Issue:10

    Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones;

1988
Lack of effect of dopamine receptor blockade on the TSH response to TRH in borderline personality disorder.
    Psychiatry research, 1987, Volume: 21, Issue:4

    Topics: Adult; Borderline Personality Disorder; Female; Haloperidol; Humans; Male; Personality Disorders; Re

1987
Catatonia in the emergency department.
    Annals of emergency medicine, 1985, Volume: 14, Issue:4

    Topics: Adult; Aged; Bipolar Disorder; Catatonia; Diagnosis, Differential; Emergency Service, Hospital; Halo

1985
Letter: Haloperidol.
    The Medical journal of Australia, 1973, Sep-08, Volume: 2, Issue:10

    Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Personality Disorders

1973
[On the prophylactic treatment of cyclothymic diseases with a carboanhydrase inhibitor (author's transl)].
    Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1973, Volume: 6, Issue:1

    Topics: Acetazolamide; Amitriptyline; Aortic Valve Stenosis; Carbonic Anhydrase Inhibitors; Haloperidol; Hea

1973
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
    Endokrinologie, 1969, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau

1969